Interventions to Slow Aging in Humans: Are We Ready?

Aging Cell

Valter D. Longo⁴  Adam Antebi²⁹  Andrzej Bartke³  Nir Barzilai¹⁹  Holly M. Brown-Borg¹⁴  Calogero Caruso⁸  Tyler J. Curiel¹⁷  Rafael de Cabo¹²  Claudio Franceschi²⁷  David Gems^2,4  Donald K. Ingram^4,7  Thomas E. Johnson^4,13  Brian K. Kennedy^4,25  Cynthia Kenyon^4,22  Samuel Klein^4,9  John J. Kopchick^4,23  Guenter Lepperdinger^4,24  Frank Madeo^4,6  Mario G. Mirisola^4,26  James R. Mitchell^5,29  Giuseppe Passarino^28,29  Karl L. Rudolph^20,29  John M. Sedivy^15,29  Gerald S. Shadel^21,29  David A. Sinclair^10,29  Stephen R. Spindler^1,29  Yousin Suh^18,29  Jan Vijg^16,29  Manlio Vinciguerra^11,29 

[1] Department of Biochemistry, University of California at Riverside, Riverside, CA, USA;Department of Genetics, Evolution and Environment, Institute of Healthy Ageing, University College London, London, UK;Department of Internal Medicine, Southern Illinois University-School of Medicine, Springfield, IL, USA;Davis School of Gerontology and Department of Biological Sciences, Longevity Institute, University of Southern California, Los Angeles, CA, USA;Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, MA, USA;Institute of Molecular Biosciences, NAWI Graz, University of Graz, Austria;Nutritional Neuroscience and Aging Laboratory, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA, USA;Immunosenescence Unit, Department of Pathobiology and Medical and Forensic Biotechnologies, University of Palermo, Palermo, Italy;Center for Human Nutrition, Washington University School of Medicine, St. Louis, MO, USA;Laboratory for Ageing Research, Department of Pharmacology, School of Medical Sciences, UNSW Australia, Sydney, NSW, Australia;Division of Medicine, University College London (UCL) – Institute for Liver and Digestive Health, Royal Free Hospital, London, UK;Experimental Gerontology Section, TGB, NIA, NIH, Baltimore, MD, USA;Institute for Behavioral Genetics, University of Colorado at Boulder, Boulder, CO, USA;Department of Basic Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND, USA;Laboratories for Molecular Medicine, Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA;Department of Genetics, Albert Einstein Medical Center, Bronx, NY, USA;Department of Medicine, University of Texas Health Science Center, San Antonio, TX, USA;Department of Genetics, Albert Einstein College of Medicine, Bronx, NY, USA;Institute for Aging Research, Albert Einstein College of Medicine, Bronx, NY, USA;Leibniz Institute for Age Research, Fritz Lipmann Institute, Jena, Germany;Department of Pathology, Yale University School of Medicine, New Haven, CT, USA;Department of Biochemistry and Biophysics, Mission Bay Genentech Hall, University of California, San Francisco, CA, USA;Department of Biomedical Sciences, Edison Biotechnology Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, USA;Institut für Alternsforschung, Universität Innsbruck, Innsbruck, Austria;Buck Institute for Research on Aging, Novato, CA, USA;Dipartimento di Biopatologia e Biotecnologie mediche, Universita' di Palermo, Palermo, Italy;DIMES-Department of Specialty, Diagnostic and Experimental Medicine, Bologna, Italy;Department of Biology, Ecology and Earth Science, University of Calabria, Rende, Italy;Max Planck Institute for Biology of Ageing, Koeln, Germany

关键词: aging;    anti‐aging;    centenarians;    longevity regulation;    dietary restriction;    lifespan studies;    longevity gene;   

DOI  :  10.1111/acel.12338

来源: Wiley

【 摘 要 】

Summary

The workshop entitled ‘Interventions to Slow Aging in Humans: Are We Ready?’ was held in Erice, Italy, on October 8–13, 2013, to bring together leading experts in the biology and genetics of aging and obtain a consensus related to the discovery and development of safe interventions to slow aging and increase healthy lifespan in humans. There was consensus that there is sufficient evidence that aging interventions will delay and prevent disease onset for many chronic conditions of adult and old age. Essential pathways have been identified, and behavioral, dietary, and pharmacologic approaches have emerged. Although many gene targets and drugs were discussed and there was not complete consensus about all interventions, the participants selected a subset of the most promising strategies that could be tested in humans for their effects on healthspan. These were: (i) dietary interventions mimicking chronic dietary restriction (periodic fasting mimicking diets, protein restriction, etc.); (ii) drugs that inhibit the growth hormone/IGF-I axis; (iii) drugs that inhibit the mTOR–S6K pathway; or (iv) drugs that activate AMPK or specific sirtuins. These choices were based in part on consistent evidence for the pro-longevity effects and ability of these interventions to prevent or delay multiple age-related diseases and improve healthspan in simple model organisms and rodents and their potential to be safe and effective in extending human healthspan. The authors of this manuscript were speakers and discussants invited to the workshop. The following summary highlights the major points addressed and the conclusions of the meeting.

【 授权许可】

CC BY   
© 2015 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.

Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.